Noramco announced it has reactivated its previously filed Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for the active pharmaceutical ingredient methylnaltrexone bromide.
Meet us at DCAT Week
Meet us at DCAT Week, the premier business development event for companies engaged in pharmaceutical development and manufacturing.
Noramco Cannabinoids Business to Become Purisys
Noramco announced today that its industry-leading cannabinoids business will become a separate company – Purisys, LLC.
Noramco at iCDP
Noramco is a proud partner of the International Cannabinoid Derived Pharmaceuticals Summit (iCDP), taking place on September 10-12, 2019 in Boston, MA.
Say Hello to Amber Burch
Amber Burch came to Noramco from a small company environment and thoroughly enjoys working at Noramco, “a very dynamic place to work with a lot of growth”.
Say Hello to Gregory Moore
Gregory Moore joined Noramco as a temp one month after retiring from the U.S. Air Force in August 2014. Within a year, he was hired to a permanent position.
Noramco Presents Comments and Answers Questions at FDA Hearing on Cannabidiol
Noramco presented testimony and answered questions at the Food and Drug Administration’s (FDA) Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds, Part 15 Public Hearing.
Nemus Bioscience Signs Agreement with Noramco
Nemus Bioscience announced an agreement with Noramco for the manufacturing and scale-up of proprietary analog of cannabidiol (CBD) licensed from the University of Mississippi.
Noramco Adds Capacity and Dual Sources of Supply for Cannabinoids
Noramco, a leader in controlled substances and cannabinoids, is adding commercial-scale capacity of dronabinol (THC) at its Athens, Georgia, United States facility. The expansion comes in response to rising demand for its highly pure cannabidiol (CBD) and dronabinol (THC) analogs of cannabis sativa.
Noramco Announces Provisional Patent Application of Proprietary Cannabidiol (CBD)
Noramco, a global leading producer of controlled substances, including cannabinoids for the pharmaceutical industry, today announced that it has filed a provisional patent application with the US Patent and Trademark Office (USPTO) directed to its proprietary pure cannabidiol (CBD) compositions.